Lexeo Therapeutics (LXEO) News Today → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free LXEO Stock Alerts $12.50 +0.34 (+2.80%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBrokers Issue Forecasts for Lexeo Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LXEO)americanbankingnews.com - April 27 at 1:30 AMBuy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancementsmarkets.businessinsider.com - April 26 at 6:05 PMResearch Analysts Offer Predictions for Lexeo Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LXEO)marketbeat.com - April 26 at 7:51 AMEquities Analysts Set Expectations for Lexeo Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:LXEO)americanbankingnews.com - April 26 at 3:50 AMLexeo Therapeutics, Inc. Forecasted to Post FY2027 Earnings of ($2.58) Per Share (NASDAQ:LXEO)marketbeat.com - April 25 at 9:13 AMLexeo Therapeutics secures rights to advance gene therapyuk.investing.com - April 24 at 2:32 PMLexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Lock-Up Period Set To End on May 1stamericanbankingnews.com - April 24 at 1:12 AMLexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathyfinance.yahoo.com - April 22 at 8:30 AMLexeo Therapeutics (NASDAQ:LXEO) Trading Down 1.5%americanbankingnews.com - April 19 at 3:20 AMLexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathymarketwatch.com - April 16 at 8:56 AMLexeo's LX2006 Gene Therapy Gets FDA Fast Track Designation; Stock Up In Pre-marketmarkets.businessinsider.com - April 16 at 8:56 AMLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathyfinance.yahoo.com - April 16 at 8:56 AMLexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathyglobenewswire.com - April 16 at 7:30 AMLexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Offseekingalpha.com - April 9 at 6:24 PMStifel Nicolaus Reaffirms Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)markets.businessinsider.com - March 14 at 1:46 AMLexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financingglobenewswire.com - March 13 at 4:22 PMOptimistic Outlook for Lexeo Therapeutics with Strong Clinical and Financial Performance Justifying Buy Ratingmarkets.businessinsider.com - March 13 at 10:44 AMRBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - March 12 at 6:21 PMLexeo Therapeutics announces $95M private equity placementmsn.com - March 11 at 1:04 PMLexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsglobenewswire.com - March 11 at 7:42 AMLexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financingglobenewswire.com - March 11 at 7:30 AMLexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by Analystsmarketbeat.com - February 13 at 3:43 AMLexeo Therapeutics Bolsters Leadership with Key Hiresmsn.com - February 6 at 7:41 AMLexeo Therapeutics announces new executive appointmentsmsn.com - February 5 at 4:12 PMLexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointmentsfinance.yahoo.com - February 5 at 9:27 AMLexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer'sseekingalpha.com - January 29 at 8:52 AMLexeo Therapeutics, Inc. (NASDAQ:LXEO) Forecasted to Earn Q2 2024 Earnings of ($0.71) Per Sharemarketbeat.com - January 19 at 8:15 AMLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - January 19 at 4:19 AMAnalysts Conflicted on These Healthcare Names: Lexeo Therapeutics, Inc. (LXEO) and Andlauer Healthcare Group (OtherANDHF)markets.businessinsider.com - January 19 at 12:08 AMmarketbeat.com - January 18 at 9:34 AMLexeo Therapeutics, Inc. Expected to Post Q1 2024 Earnings of ($0.71) Per Share (NASDAQ:LXEO)marketbeat.com - January 18 at 7:31 AMLXEO Lexeo Therapeutics, Inc.seekingalpha.com - January 7 at 12:58 AMLexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC Capitalmarkets.businessinsider.com - January 6 at 9:57 AMLexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 10:35 AMLexeo gets orphan drug, fast track status for cardiac gene therapyseekingalpha.com - December 19 at 7:16 PMLexeo Therapeutics Says FDA Grants Fast Track And Orphan Drug Designation To LX2020markets.businessinsider.com - December 18 at 7:42 AMLexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)finance.yahoo.com - December 18 at 7:42 AMLeerink Partnrs Weighs in on Lexeo Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:LXEO)marketbeat.com - December 14 at 6:48 AMStable Execution and Positive Clinical Progress Support $19 Price Target for Lexeo Therapeuticsmarkets.businessinsider.com - December 14 at 1:07 AMLexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programsfinance.yahoo.com - December 13 at 9:56 AMLexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlightsfinance.yahoo.com - December 11 at 11:59 AMLexeo Therapeutics Inc LXEOmorningstar.com - December 8 at 3:54 PMmarketbeat.com - November 8 at 9:33 AM Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy LXEO Media Mentions By Week LXEO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.470.34▲Average Medical News Sentiment LXEO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼152▲LXEO Articles Average Week Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Voyager Therapeutics News Today Tourmaline Bio News Today iTeos Therapeutics News Today Adaptive Biotechnologies News Today Replimune Group News Today C4 Therapeutics News Today Editas Medicine News Today Taysha Gene Therapies News Today Fate Therapeutics News Today Aura Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
